Infantile myofibromatosis (IM) is characterized by solitary musculoskeletal nodules presenting during infancy but can manifest as multiple lesions with visceral involvement. Multicentric IM with visceral involvement carries a high risk of mortality and there is no consensus on treatment. We present a case of a patient with multicentric IM and pulmonary involvement who progressed on several chemotherapeutic regimens and subsequently had a complete response to sorafenib and later imatinib. This report describes the novel use of sorafenib and imatinib to treat generalized IM and the role of continued tyrosine kinase inhibitor therapy to maintain remission.
Bibliographical noteFunding Information:
This work was supported by the Mayo Clinic Children's Research Center.
© 2020 Wiley Periodicals, Inc.
Copyright 2020 Elsevier B.V., All rights reserved.
- infantile myofibromatosis
- soft tissue tumor
- targeted therapy